Literature DB >> 2866784

The effect of repeated doses of temazepam and nitrazepam on human psychomotor performance.

G Tedeschi, A N Griffiths, A T Smith, A Richens.   

Abstract

The effects of six nightly doses of temazepam (20 mg), nitrazepam (10 mg) and placebo on saccadic eye movements, critical flicker fusion, choice reaction time and on subjective feelings were studied in a double blind cross-over study in eight volunteers. Testing was performed on nights 1 and 6 of treatment. Nitrazepam, a benzodiazepine with a long elimination half-life produced a residual performance impairment on night 1 that had disappeared by night 6, despite higher serum concentrations of the drug on the sixth night of treatment. Temazepam, with a shorter elimination half-life produced no significant performance impairment on night 1, but by night 6 a significant impairment of saccadic eye movements (P less than 0.05), was seen 1 h after drug intake. We conclude that tolerance developed to the sedative action of nitrazepam over the 6 night period of the study. No evidence of tolerance was seen with temazepam.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866784      PMCID: PMC1400899          DOI: 10.1111/j.1365-2125.1985.tb05078.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  A sub-chronic study of the subjective quality of sleep and psychological measures of performance on the morning following night time medication with temazepam.

Authors:  I Hindmarch
Journal:  Arzneimittelforschung       Date:  1976

2.  The benzodiazepine receptor in normal and pathological human brain.

Authors:  H Möhler; T Okada
Journal:  Br J Psychiatry       Date:  1978-09       Impact factor: 9.319

3.  Effects of hypnotic and sleep-inducing drugs on objective assessments of human psychomotor performance and subjective appraisals of sleep and early morning behaviour.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Absence of platelet monamine oxidase inhibition during amitriptyline or zimelidine treatment.

Authors:  M A Reveley; V Glover; M Slander; A Coppen
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

5.  Activity of brain stem neurons during eye movements of alert monkeys.

Authors:  E S Luschei; A F Fuchs
Journal:  J Neurophysiol       Date:  1972-07       Impact factor: 2.714

6.  Visual analogue scales and drug effects in man.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

7.  Nitrazepam: lastingly effective but trouble on withdrawal.

Authors:  K Adam; L Adamson; V Brezinová; W M Hunter
Journal:  Br Med J       Date:  1976-06-26

8.  Benzodiazepine hypnotics remain effective for 24 weeks.

Authors:  I Oswald; C French; K Adam; J Gilham
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-20

9.  Brain specific benzodiazepine receptors.

Authors:  C Braestrup; R F Squires
Journal:  Br J Psychiatry       Date:  1978-09       Impact factor: 9.319

10.  Influence of age and previous use of diazepam dosage required for endoscopy.

Authors:  H G Giles; S M MacLeod; J R Wright; E M Sellers
Journal:  Can Med Assoc J       Date:  1978-03-04       Impact factor: 8.262

View more
  3 in total

1.  Saccadic eye movements analysis as a measure of drug effect on central nervous system function.

Authors:  G Tedeschi; A Quattrone; V Bonavita
Journal:  Ital J Neurol Sci       Date:  1986-04

2.  Effects of oxazepam on eye movements and performance in vigilance tasks with static and dynamic stimuli.

Authors:  T H van Leeuwen; M N Verbaten; H S Koelega; G Camfferman; J van der Gugten; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 3.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.